C-reactive protein as a predictor of disease in smokers and former smokers

International Journal of Clinical Practice

Volumn 63, Issue 11, 2009, Pages 1634-1641

  Tonstad, S ^a   Cowan, J L ^b  

^a LOMA LINDA UNIVERSITY   (United States)

^b Envision House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; BIOLOGICAL MARKER; CYTOKINE;

CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COMORBIDITY; DISEASE COURSE; HUMAN; INFLAMMATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; ACUTE DISEASE; ADULT; AGE; AGED; BIOASSAY; BLOOD; CHRONIC DISEASE; FEMALE; MALE; METABOLISM; MIDDLE AGED; RISK ASSESSMENT; SMOKING;

ACUTE DISEASE; ADULT; AGE FACTORS; AGED; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHRONIC DISEASE; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RISK ASSESSMENT; SMOKING; SMOKING CESSATION;

EID: 70349971613     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02179.x     Document Type: Review

References (64)

1. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER Package. Geneva, World Health Organisation, 2008.
2. Centers for Disease Control and Prevention. 2004 Surgeon General's Report - The Health Consequences of Smoking. Atlanta, GA : Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004. http://www.cdc.gov/tobacco/data- statistics/sgr/sgr-2004/index.htm (accessed August 2009).
3. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation 1997 96 : 3243 3247.
4. Smith SC Jr., Milani RV, Arnett DK et al. Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors. Circulation 2004 109 : 2613 2616.
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002 105 : 1135 1143.
6. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999 340 : 115 126.
7. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007 370 : 765 773.
8. Majka DS, Holers VM. Cigarette smoking and the risk of systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2006 65 : 561 563.
9. Lakatos PL, Szamosi T, Lakatos L. Smoking in inflammatory bowel diseases: good, bad or ugly? World J Gastroenterol 2007 13 : 6134 6139.
10. Casas JP, Shah T, Hingorani AD et al. C-reactive protein and coronary heart disease: a critical review. J Intern Med 2008 264 : 295 314.
11. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004 279 : 48487 48490.
12. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003 111 : 1805 1812.
13. Ouchi N, Kihara S, Funahashi T et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003 107 : 671 674.
14. Calabro P, Chang DW, Willerson JT et al. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005 46 : 1112 1113.
15. Zhang YX, Cliff WJ, Schoefl GI et al. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 1999 145 : 375 379.
16. Young DP, Kushner I, Samols D. Binding of C/EBPbeta to the C-reactive protein (CRP) promoter in Hep3B cells is associated with transcription of CRP mRNA. J Immunol 2008 181 : 2420 2427.
17. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 1999 7 : 169 177.
18. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993 91 : 1351 1357.
19. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001 103 : 1813 1818.
20. Ridker PM. Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice. Am Heart Hosp J 2004 2 : 4 9.
21. Lowe GD, Pepys MB. C-reactive protein and cardiovascular disease: weighing the evidence. Curr Atheroscler Rep 2006 8 : 421 428.
22. Vanderschueren S, Deeren D, Knockaert DC et al. Extremely elevated C-reactive protein. Eur J Intern Med 2006 17 : 430 433.
23. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004 350 : 1387 1397.
24. Pepys MB. CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol 2005 25 : 1091 1094.
25. Yanbaeva DG, Dentener MA, Creutzberg EC et al. Systemic effects of smoking. Chest 2007 131 : 1557 1566.
26. van Eeden SF, Hogg JC. The response of human bone marrow to chronic cigarette smoking. Eur Respir J 2000 15 : 915 921.
27. van Eeden SF, Yeung A, Quinlam K et al. Systemic response to ambient particulate matter: relevance to chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005 2 : 61 7.
28. van der Vaart H, Postma DS, Timens W et al. Acute effects of cigarette smoking on inflammation in healthy intermittent smokers. Respir Res 2005 6 : 22.
29. Das I. Raised C-reactive protein levels in serum from smokers. Clin Chim Acta 1985 153 : 9 13.
30. Helmersson J, Larsson A, Vessby B et al. Active smoking and a history of smoking are associated with enhanced prostaglandin F-2 alpha, interleukin-6 and F-2-isoprostane formation in elderly men. Atherosclerosis 2005 181 : 201 207.
31. Wannamethee SG, Lowe GD, Shaper AG et al. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 2005 26 : 1765 1773.
32. Lowe GDO, Yarnell JWG, Rumley A et al. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the speedwell study - are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 2001 21 : 603 610.
33. Ohsawa M, Okayama A, Nakamura M et al. CRP levels are elevated in smokers but unrelated to the number of cigarettes and are decreased by long-term smoking cessation in male smokers. Prev Med 2005 41 : 651 656.
34. Fröhlich M, Sund M, Lowel H et al. Independent association of various smoking characteristics with markers of systemic inflammation in men - results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003 24 : 1365 1372.
35. Bermudez EA, Rifai N, Buring JE et al. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol 2002 89 : 1117 1119.
36. Dietrich T, Garcia RI, de Pablo P et al. The effects of cigarette smoking on C-reactive protein concentrations in men and women and its modification by exogenous oral hormones in women. Eur J Cardiovasc Prev Rehabil 2007 14 : 694 700.
37. Ridker PM. Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice. Am Heart Hosp J 2004 2 : 4 9.
38. Ridker PM, Silvertown JD. Inflammation, C-reactive protein, and atherothrombosis. J Periodontol 2008 79 : 1544 1551.
39. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004 43 : 1731 1737.
40. Zieske AW, McMahan CA, McGill HC Jr. et al. Smoking is associated with advanced coronary atherosclerosis in youth. Atherosclerosis 2005 180 : 87 92.
41. Zieske AW, Tracy RP, McMahan CA et al. Elevated serum C-reactive protein levels and advanced atherosclerosis in youth. Arterioscler Thromb Vasc Biol 2005 25 : 1237 1243.
42. Man SFP, Connett JE, Anthonisen NR et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006 61 : 849 853.
43. de Torres JP, Pinto-Plata V, Casanova C et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008 133 : 1336 1343.
44. Pinto-Plata VM, Müllerova H, Toso JF et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006 61 : 23 8.
45. Haverkate F, Thompson SG, Pyke SD et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997 349 : 462 466.
46. Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007 61 : 824 833.
47. Heikkilä K, Harris R, Lowe G et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009 20 : 15 26.
48. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009 27 : 2217 2224.
49. Zedler BK, Kinser R, Oey J et al. Biomarkers of exposure and potential harm in adult smokers of 3-7 mg tar yield (Federal Trade Commission) cigarettes and in adult non-smokers. Biomarkers 2006 11 : 201 220.
50. Cushman M, Legault C, Barrett-Connor E et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999 100 : 717 722.
51. Cushman M, Meilahn EN, Psaty BM et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999 19 : 893 899.
52. O'Loughlin J, Lambert M, Karp I et al. Association between cigarette smoking and C-reactive protein in a representative, population-based sample of adolescents. Nicotine Tob Res 2008 10 : 525 532.
53. Wilkinson JD, Lee DJ, Arheart KL. Secondhand smoke exposure and C-reactive protein levels in youth. Nicotine Tob Res 2007 9 : 305 307.
54. Panagiotakos DB, Pitsavos C, Chrysohoou C et al. Effect of exposure to secondhand smoke on markers of inflammation: the ATTICA study. Am J Med 2004 116 : 145 150.
55. Venn A, Britton J. Exposure to secondhand smoke and biomarkers of cardiovascular disease risk in never-smoking adults. Circulation 2007 115 : 990 995.
56. Hastie CE, Haw S, Pell JP. Impact of smoking cessation and lifetime exposure on C-reactive protein. Nicotine Tob Res 2008 10 : 637 642.
57. Crook MA, Scott DA, Stapleton JA et al. Circulating concentrations of C-reactive protein and total sialic acid in tobacco smokers remain unchanged following one year of validated smoking cessation. Eur J Clin Invest 2000 30 : 861 865.
58. Hammett CJ, Prapavessis H, Baldi JC et al. Variation in blood levels of inflammatory markers related and unrelated to smoking cessation in women. Prev Cardiol 2007 10 : 68 75.
59. Joseph AM, Hecht SS, Murphy SE et al. Smoking reduction fails to improve clinical and biological markers of cardiac disease: a randomized controlled trial. Nicotine Tob Res 2008 10 : 471 481.
60. Hage FG, Szalai AJ. C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk. J Am Coll Cardiol 2007 50 : 1115 1122.
61. Szalai AJ, McCrory MA, Cooper GS et al. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002 3 : 14 9.
62. Danik JS, Ridker PM. Genetic determinants of C-reactive protein. Curr Atheroscler Rep 2007 9 : 195 203.
63. Pulkkinen K, Malm T, Turunen M et al. Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett 2008 582 : 2397 2401.
64. Emerging Risk Factors Collaboration, Danesh J, Erqou S et al. The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol 2007 22 : 839 869.